Ricardo Osorio

Array ( [id] => 18612402 [patent_doc_number] => 20230279134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => ANTI-CD137 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/051761 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034221 [patent_doc_number] => 20240084036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => MONOCLONAL ANTIBODIES AGAINST C-MET [patent_app_type] => utility [patent_app_number] => 17/972867 [patent_app_country] => US [patent_app_date] => 2022-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17972867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612401 [patent_doc_number] => 20230279133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/047240 [patent_app_country] => US [patent_app_date] => 2022-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638085 [patent_doc_number] => 12168686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Method of treating cancer using disulfide-linked trimeric OX40L [patent_app_type] => utility [patent_app_number] => 17/966884 [patent_app_country] => US [patent_app_date] => 2022-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 22 [patent_no_of_words] => 10382 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17966884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19195298 [patent_doc_number] => 11992516 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-28 [patent_title] => Compositions comprising IL-15-based molecules and immune checkpoint inhibitor antibodies [patent_app_type] => utility [patent_app_number] => 18/045572 [patent_app_country] => US [patent_app_date] => 2022-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 79 [patent_no_of_words] => 30659 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582945 [patent_doc_number] => 20230265203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => USE OF ANTI-CD40 ANTIBODIES FOR TREATMENT OF LUPUS NEPHRITIS [patent_app_type] => utility [patent_app_number] => 17/962099 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586436 [patent_doc_number] => 20240383993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => ANTI-4-1BB NANOBODIES [patent_app_type] => utility [patent_app_number] => 18/687277 [patent_app_country] => US [patent_app_date] => 2022-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18687277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18221630 [patent_doc_number] => 20230060624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => ANTI-CD30L ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/822598 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19291604 [patent_doc_number] => 12030951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-09 [patent_title] => Anti-OX40 antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 17/820682 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 21248 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18184532 [patent_doc_number] => 20230045262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-4-1BB CLONE 20H4.9 [patent_app_type] => utility [patent_app_number] => 17/819867 [patent_app_country] => US [patent_app_date] => 2022-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545329 [patent_doc_number] => 11718669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Anti-TIGIT and anti-CD96 antibodies [patent_app_type] => utility [patent_app_number] => 17/818840 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 177 [patent_no_of_words] => 84929 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18268727 [patent_doc_number] => 20230089969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 [patent_app_type] => utility [patent_app_number] => 17/817033 [patent_app_country] => US [patent_app_date] => 2022-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179198 [patent_doc_number] => 20230039927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS [patent_app_type] => utility [patent_app_number] => 17/816946 [patent_app_country] => US [patent_app_date] => 2022-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50111 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18270354 [patent_doc_number] => 20230091596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => MITIGATION AND REVERSAL OF INTESTINAL FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION [patent_app_type] => utility [patent_app_number] => 17/814704 [patent_app_country] => US [patent_app_date] => 2022-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945802 [patent_doc_number] => 20220332819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 17/849101 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448966 [patent_doc_number] => 20240309096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF [patent_app_type] => utility [patent_app_number] => 18/566391 [patent_app_country] => US [patent_app_date] => 2022-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855589 [patent_doc_number] => 12258412 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies [patent_app_type] => utility [patent_app_number] => 17/828847 [patent_app_country] => US [patent_app_date] => 2022-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 37673 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17828847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867115 [patent_doc_number] => 20220289850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => ANTI-AVBETA8 ANTIBODIES AND COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/743578 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20057410 [patent_doc_number] => 20250195632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITION AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/560272 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077567 [patent_doc_number] => 12351617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Immune cells comprising truncated NKG2D chimeric receptors [patent_app_type] => utility [patent_app_number] => 17/740899 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 57 [patent_no_of_words] => 27096 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740899 [rel_patent_id] =>[rel_patent_doc_number] =>)